BRNS BARINTHUS BIO
BARINTHUS BIO (BRNS) is expected to report earnings on November 5, 2026, before the market open.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About BARINTHUS BIO
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases. The company's product pipeline includes VTP-300, VTP-200, VTP-1000, VTP-850 and VTP-1100. Barinthus Biotherapeutics plc, formerly known as Vaccitech plc, is based in OXFORD, United Kingdom.
Sector
Healthcare
Industry
Biotechnology